AMGN

AMGEN INC

Healthcare · Biotech

$418.13Sep 28, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Strong evidence · 3 sources

Why it matters

AMGEN INC shows stable business momentum based on AlphaOS pipeline evidence, with weak management execution.

Why it matters: Revenue +9% YoY in Q2 FY2026.

TrajectoryStable
ExecutionWeak

2 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue +9% YoY in Q2 FY2026
  • CFO Retirement and Succession (Q1 FY2026)

Pipeline evidence · 0d ago

AMGN's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on AMGN.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full AMGN earnings analysis

Reported figures for AMGEN INC — research only, not investment advice.

Revenue YoY
+9.5%
EPS YoY
+64.9%
vs estimates
Miss

Latest Intelligence

Updated

What happened recently for AMGEN INC (AMGN) — events, not interpretation.

Event
Reported Q2 2026 revenue +10% YoY, miss vs estimates.
Also
Last session September 28, 2026 at $418.13.
Source
Q2 2026 earnings

Research & analysis only — not investment advice.

Building company intelligence…

AMGEN INC (AMGN)

Healthcare · Biotech

Investment Snapshot above is the primary AlphaOS analysis for AMGEN INC — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Industry:
Biotech
Market cap:
$226.05B
Revenue:
$10.05B

AMGN earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow AMGEN INC through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

AMGEN INC (AMGN) in AlphaOS research

Connected companies and research pages from the AlphaOS knowledge graph.

Structured stock intelligence for companies connected to this research.